Fig. 5

DAC + 5-FU@HFn impaired the oncogenesis of CML cells in vivo. (A) A CML-HSC-NSG mouse model was established and subjected to a designated treatment regimen. (B) The body weights of the mice were recorded for 90 days. (C) The maximum white blood cell (WBC) counts in the peripheral blood of the mice were measured. (D) The percentage of CD45⁺ cells in the bone marrow of the mice was detected via flow cytometry (FCM). (E) The weights and sizes of the liver and spleen were measured in CML mice. (F) Liver, spleen, and bone marrow (BM) samples from CML mice were examined via Wright‒Giemsa staining. The infiltrating leukemic cells are indicated by arrows. Scale bar: 10 μm. (G) Immunofluorescence staining was performed to analyze the protein expression of BCR/ABL in the liver, spleen, and bone marrow of CML mice. Scale bar: 20 μm. All the data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001